Phu le, MD
Neurology · Fort Myers, FLNPI 1073046371
Payments from drug & device makers
Across 74 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$329
- SK Life Science, Inc.$227
- Neurocrine Biosciences, Inc.$171
- Sanofi$101
- Biogen$72
- Amgen$72
- plus $367 from 14 others
What the payments were for
- Food & beverage$1,32699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $329 |
| SK Life Science, Inc. | 12 | $227 |
| Neurocrine Biosciences, Inc. | 10 | $171 |
| Sanofi | 4 | $101 |
| Biogen | 4 | $72 |
| Amgen | 4 | $72 |
| Amneal Pharmaceuticals LLC | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| AstraZeneca(2 entities) | 2 | $33 |
| Medtronic | 2 | $33 |
| Bristol Myers Squibb | 2 | $29 |
| Impel Pharmaceuticals Inc. | 2 | $26 |
| Bayer | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$1,338 in reported general payments places this provider in the 40th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 46 | $1,258 |
| Carbamazepine ErCarbamazepine | 13 | $743 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 31 | $543 |
| Memantine Hcl | 24 | $434 |
| Topiramate | 32 | $353 |
| Sumatriptan Succinate | 18 | $322 |
| Donepezil Hcl | 26 | $248 |
| Baclofen | 13 | $218 |
| Propranolol Hcl | 15 | $158 |
| RizatriptanRizatriptan Benzoate | 11 | $157 |
| Atorvastatin Calcium | 30 | $117 |
| Gabapentin | 14 | $116 |
| Duloxetine Hcl | 13 | $107 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fort Myers
- Wendy BondFort Myers$14.7M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.